CA2652516A1 - Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma - Google Patents
Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma Download PDFInfo
- Publication number
- CA2652516A1 CA2652516A1 CA002652516A CA2652516A CA2652516A1 CA 2652516 A1 CA2652516 A1 CA 2652516A1 CA 002652516 A CA002652516 A CA 002652516A CA 2652516 A CA2652516 A CA 2652516A CA 2652516 A1 CA2652516 A1 CA 2652516A1
- Authority
- CA
- Canada
- Prior art keywords
- administered
- dose
- day
- dacarbazine
- thymosin alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 46
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 108010078233 Thymalfasin Proteins 0.000 title claims description 52
- 102400000800 Thymosin alpha-1 Human genes 0.000 title claims description 52
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 title claims description 52
- 229960004231 thymalfasin Drugs 0.000 title claims description 52
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims abstract description 61
- 229960003901 dacarbazine Drugs 0.000 claims abstract description 47
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract description 40
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract description 40
- 206010027476 Metastases Diseases 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 10
- 239000011885 synergistic combination Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 2
- 101800001530 Thymosin alpha Proteins 0.000 abstract 1
- 230000004044 response Effects 0.000 description 59
- 238000007920 subcutaneous administration Methods 0.000 description 16
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 15
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 206010027458 Metastases to lung Diseases 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010043417 Therapeutic response unexpected Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/32—Thymopoietins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/424,475 US20070292392A1 (en) | 2006-06-15 | 2006-06-15 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
| US11/424,475 | 2006-06-15 | ||
| US11/734,592 | 2007-04-12 | ||
| US11/734,592 US8017129B2 (en) | 2006-06-15 | 2007-04-12 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
| PCT/EP2007/053712 WO2007144218A1 (en) | 2006-06-15 | 2007-04-17 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2652516A1 true CA2652516A1 (en) | 2007-12-21 |
Family
ID=38323947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002652516A Abandoned CA2652516A1 (en) | 2006-06-15 | 2007-04-17 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8017129B2 (enExample) |
| EP (1) | EP2032153A1 (enExample) |
| JP (1) | JP2009539916A (enExample) |
| KR (1) | KR20090020646A (enExample) |
| AR (1) | AR061352A1 (enExample) |
| AU (1) | AU2007260145A1 (enExample) |
| CA (1) | CA2652516A1 (enExample) |
| HR (1) | HRP20090010A2 (enExample) |
| IL (1) | IL195955A0 (enExample) |
| MX (1) | MX2008015145A (enExample) |
| NO (1) | NO20090238L (enExample) |
| RU (1) | RU2009101026A (enExample) |
| TW (1) | TW200808327A (enExample) |
| WO (1) | WO2007144218A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7260764B2 (en) * | 2002-11-26 | 2007-08-21 | Qualcomm Incorporated | Multi-channel transmission and reception with block coding in a communication system |
| US20080300166A1 (en) * | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
| AU2008338594A1 (en) * | 2007-12-14 | 2009-06-25 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA) |
| ES2356865T3 (es) * | 2008-10-16 | 2011-04-13 | Orion Tech Anstalt | Tratamiento de residuos líquidos que contienen metales pesados. |
| EP3256150B1 (en) * | 2015-02-09 | 2020-12-09 | SciClone Pharmaceuticals International Ltd. | Thymosin alpha 1 for use in treatment of cystic fibrosis |
| US9861833B1 (en) * | 2017-03-30 | 2018-01-09 | Norman H. Anderson | Methods of treating melanoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888980A (en) * | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
| US6462017B1 (en) | 2000-05-01 | 2002-10-08 | Sciclone Pharmaceuticals, Inc. | Method of reducing side effects of chemotherapy in cancer patients |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| UA80957C2 (en) | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| US7101598B2 (en) * | 2002-05-22 | 2006-09-05 | Om Nova Solutions Inc. | Self adhering membrane for roofing applications |
| UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| US20080300166A1 (en) * | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
-
2007
- 2007-04-12 US US11/734,592 patent/US8017129B2/en active Active
- 2007-04-17 JP JP2009514721A patent/JP2009539916A/ja not_active Withdrawn
- 2007-04-17 AU AU2007260145A patent/AU2007260145A1/en not_active Abandoned
- 2007-04-17 WO PCT/EP2007/053712 patent/WO2007144218A1/en not_active Ceased
- 2007-04-17 MX MX2008015145A patent/MX2008015145A/es not_active Application Discontinuation
- 2007-04-17 EP EP07728177A patent/EP2032153A1/en not_active Withdrawn
- 2007-04-17 HR HR20090010A patent/HRP20090010A2/xx not_active Application Discontinuation
- 2007-04-17 KR KR1020087031799A patent/KR20090020646A/ko not_active Withdrawn
- 2007-04-17 CA CA002652516A patent/CA2652516A1/en not_active Abandoned
- 2007-04-17 RU RU2009101026/15A patent/RU2009101026A/ru not_active Application Discontinuation
- 2007-04-23 TW TW096114301A patent/TW200808327A/zh unknown
- 2007-06-13 AR ARP070102577A patent/AR061352A1/es unknown
-
2008
- 2008-12-15 IL IL195955A patent/IL195955A0/en unknown
-
2009
- 2009-01-14 NO NO20090238A patent/NO20090238L/no not_active Application Discontinuation
- 2009-03-31 US US12/415,589 patent/US8029799B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20070292393A1 (en) | 2007-12-20 |
| EP2032153A1 (en) | 2009-03-11 |
| MX2008015145A (es) | 2008-12-15 |
| HRP20090010A2 (en) | 2009-02-28 |
| KR20090020646A (ko) | 2009-02-26 |
| AR061352A1 (es) | 2008-08-20 |
| IL195955A0 (en) | 2009-09-01 |
| WO2007144218A1 (en) | 2007-12-21 |
| RU2009101026A (ru) | 2010-07-20 |
| NO20090238L (no) | 2009-03-10 |
| US8017129B2 (en) | 2011-09-13 |
| TW200808327A (en) | 2008-02-16 |
| AU2007260145A1 (en) | 2007-12-21 |
| US20090186000A1 (en) | 2009-07-23 |
| JP2009539916A (ja) | 2009-11-19 |
| US8029799B2 (en) | 2011-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fossä et al. | Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study | |
| US11633385B2 (en) | Combination compositions for treatment of cancer | |
| US8029799B2 (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma | |
| CA2319872C (en) | Pharmaceutical composition for the treatment of hepatocellular carcinoma | |
| JP2020055884A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| EP1201247B1 (en) | Treatment of metastatic renal cell carcinoma | |
| Li et al. | The effect of saikosaponin D on doxorubicin pharmacokinetics and its MDR reversal in MCF-7/adr cell xenografts. | |
| US8642026B2 (en) | Methods and compositions for contributing to the treatment of cancers | |
| JPWO2019016928A1 (ja) | がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤 | |
| US20070292392A1 (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma | |
| KR20220169413A (ko) | 타이람과 구리를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 | |
| HK1129840A (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma | |
| EP4506015A1 (en) | Combination of a mps1 inhibitor and an antibody drug conjugate | |
| AU2018354364A1 (en) | SSTR-targeted conjugates and formulations thereof | |
| AU2008240300B2 (en) | Methods and compositions for contributing to the treatment of cancers | |
| EP2144607B1 (en) | Compositions for contributing to the treatment of cancers | |
| EP3359255B1 (en) | Combination therapies for treating cancer | |
| Bavec | Insulin, Other Hypoglycaemic Drugs, and Glucagon | |
| EP1226824A1 (en) | Use of thalidomide for the treatment of hepatocellular carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130417 |